121124-96-7

Usage

Uses

Used in Organic Chemistry Research:
2-(2-(benzyloxy)-5-bromophenyl)-1,3-dioxane is utilized as a key intermediate in organic synthesis for its capacity to contribute to the formation of complex molecular structures. Its presence in reactions can facilitate the creation of new compounds with potential applications across various chemical domains.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 2-(2-(benzyloxy)-5-bromophenyl)-1,3-dioxane serves as a valuable precursor in the development of new drugs. Its unique structure allows it to be a component in the synthesis of molecules that could exhibit therapeutic effects, pending further exploration into its pharmacological properties.
Used in the Synthesis of Biologically Active Molecules:
2-(2-(benzyloxy)-5-bromophenyl)-1,3-dioxane is employed as a synthetic building block for biologically active molecules due to its ability to be incorporated into diverse chemical entities that may possess significant biological activity. This makes it a candidate for further research and development in creating new pharmaceuticals and bioactive compounds.
Further research is essential to fully uncover the potential applications and effects of 2-(2-(benzyloxy)-5-bromophenyl)-1,3-dioxane across different fields, ensuring that its use is optimized and its benefits are maximized in scientific and medical advancements.

Upstream product

• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 1761-61-1 5-bromosalicyclaldehyde 
• 121124-94-5 2-benzyloxy-5-bromobenzaldehyde 
• 504-63-2 trimethyleneglycol 

Downstream Products

• 134038-79-2 4,4'-Dibenzyloxy-3-(1,3-dioxane-2-yl)-3'-(1,3-dithiane-2-yl)biphenyl 
• 146335-27-5 4,4'-dibenzyloxy-3-(1,3-dioxan-2-yl)-3'-(methoxycarbonyl)biphenyl 
• 143164-82-3 4,4'-dibenzyloxy-3-<(S)-2-(tert-butoxycarbonylamino)-2-methoxycarbonyl-(R)-1-hydroxyethyl>biphenyl-3'-carbaldehyde 
• 1027532-24-6 (2S,3R)-2-Amino-3-{4,4'-bis-benzyloxy-3'-[(S)-2-benzyloxycarbonylamino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethyl]-biphenyl-3-yl}-3-hydroxy-propionic acid methyl ester 
• 143164-83-4 4,4'-dibenzyloxy-3-<(S)-2-(tert-butoxycarbonylamino)-2-(methoxycarbonyl)-(R)-1-hydroxyethyl>-3'-<(Z)-2-(benzyloxycarbonylamino)-2-(trimethylsilylethoxycarbonyl)vinyl>biphenyl 
• 143164-84-5 3-<(S)-2-(benzyloxycarbonylamino)-2-(trimethylsilylethoxycarbonyl)ethyl>-3'-<(S)-2-(tert-butoxycarbonylamino)-2-(methoxycarbonyl)-(R)-1-hydroxyethyl>-4,4'-dibenzyloxybiphenyl 
• 146388-29-6 (2S,3R)-2-((2S,4R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-4-hydroxy-pentanoylamino)-3-[4,4'-bis-benzyloxy-3'-((S)-2-benzyloxycarbonylamino-2-pentafluorophenyloxycarbonyl-ethyl)-biphenyl-3-yl]-3-hydroxy-propionic acid methyl ester 
• 146335-29-7 4,4'-Bis-benzyloxy-3'-[1,3]dioxan-2-yl-biphenyl-3-carbonyl chloride 
• 146335-28-6 4,4'-dibenzyloxy-3-(1,3-dioxan-2-yl)-3'-carboxybiphenyl 
• 146335-30-0 4,4'-dibenzyloxy-3-<(R,S)-2-(tert-butoxycarbonylamino)-2-methoxycarbonyl-1-oxoethyl>-3'-(1,3-dioxan-2-yl)biphenyl 
• 146388-31-0 (7R,8S,11S,14S)-5,17-Bis-benzyloxy-14-benzyloxycarbonylamino-11-((R)-3-benzyloxycarbonylamino-2-hydroxy-propyl)-7-hydroxy-10,13-dioxo-9,12-diaza-tricyclo[14.3.1.1^2,6]henicosa-1⁽¹⁹⁾,2⁽²¹⁾,3,5,16⁽²⁰⁾,17-hexaene-8-carboxylic acid 
• 146388-30-9 (7R,8S,11S,14S)-5,17-Bis-benzyloxy-14-benzyloxycarbonylamino-11-((R)-3-benzyloxycarbonylamino-2-hydroxy-propyl)-7-hydroxy-10,13-dioxo-9,12-diaza-tricyclo[14.3.1.1^2,6]henicosa-1⁽¹⁹⁾,2⁽²¹⁾,3,5,16⁽²⁰⁾,17-hexaene-8-carboxylic acid methyl ester 
• 871206-25-6 (2S,3R)-2-((2S,4R)-2-Amino-5-benzyloxycarbonylamino-4-hydroxy-pentanoylamino)-3-[4,4'-bis-benzyloxy-3'-((S)-2-benzyloxycarbonylamino-2-pentafluorophenyloxycarbonyl-ethyl)-biphenyl-3-yl]-3-hydroxy-propionic acid methyl ester 
• 143164-86-7 C₆₇H₈₀N₄O₁₅Si 

Relevant academic research and scientific papers

Desymmetrization of Diarylmethylamido Bis(phenols) through Peptide-Catalyzed Bromination: Enantiodivergence as a Consequence of a 2 amu Alteration at an Achiral Residue within the Catalyst

Diarylmethylamido bis(phenols) have been subjected to peptide-catalyzed, enantioselective bromination reactions. Desymmetrization of compounds in this class has been achieved such that enantioenriched products may be isolated with up to 97:3 er. Mechanist

Scalable synthesis of the desoxy-biphenomycin B core

We describe the evolution of a kilogram-scale synthesis of the protected cyclic tripeptide desoxy-biphenomycin B, based on an early discovery route. The retrosynthetic concept included a macrolactamization strategy to build the core ring system of biphenomycin B in combination with a double catalytic asymmetric hydrogenation protocol for the construction of the ansa-tripeptide precursor. Eventually, the kilogram process comprised a 16-step sequence with an overall yield for the longest linear sequence of 19.5%.

Total synthesis of the biphenomycins; III. Synthesis of biphenomycin B

The total synthesis of the cyclopeptide biphenomycin B (1b), a compound exhibiting a potent antibacterial activity against Gram-positive bacteria, is described. The non-proteinogenic amino acid (S,S)-diisotyrosine (2) was prepared by enantioselective hydrogenation of the corresponding didehydroamino acids. The 15-membered ansa ring was obtained in 85% yield within 5 minutes by ring closure of the appropriate linear pentafluorophenyl ester in the two phase system chloroform-aqueous sodium hydrogen carbonate without dilution.

The Synthesis of Biphenomycin B

Biphenomycin B, a highly potent antibiotic against Gram-negative, β-lactam-resistant bacteria, which was previously isolated from culture filtrates of Streptomyces griseorubiginosus No. 43708, has now been synthesized.